Precipio Terminates Its ATM
Precipio (NASDAQ:PRPO), a specialty cancer diagnostics company, has announced the termination of its At-The-Market (ATM) instrument with Alliance Global Partners (AGP). The decision reflects the company's improved financial position, marked by the elimination of negative cash flow from operations and recent increases in cash balance.
CEO Ilan Danieli emphasized that the company is now stronger and no longer needs to rely on the ATM tool for capital raises, demonstrating management's commitment to enhancing shareholder value.
Precipio (NASDAQ:PRPO), una società specializzata in diagnostica oncologica, ha comunicato la cessazione dello strumento At-The-Market (ATM) con Alliance Global Partners (AGP). La decisione riflette il miglioramento della posizione finanziaria dell'azienda, evidenziato dall'eliminazione del flusso di cassa operativo negativo e dai recenti aumenti della disponibilità di cassa.
Il CEO Ilan Danieli ha sottolineato che l'azienda è ora più solida e non necessita più di fare affidamento sullo strumento ATM per le raccolte di capitale, a dimostrazione dell'impegno del management a incrementare il valore per gli azionisti.
Precipio (NASDAQ:PRPO), una empresa especializada en diagnóstico del cáncer, ha anunciado la terminación de su instrumento At-The-Market (ATM) con Alliance Global Partners (AGP). La decisión refleja la mejora en la posición financiera de la compañía, marcada por la eliminación del flujo de caja operativo negativo y los recientes incrementos en el saldo de efectivo.
El CEO Ilan Danieli enfatizó que la compañía está ahora más fuerte y ya no necesita depender de la herramienta ATM para las captaciones de capital, demostrando el compromiso de la dirección con el aumento del valor para los accionistas.
Precipio (NASDAQ:PRPO))는 암 전문 진단 회사로서 Alliance Global Partners(AGP)와의 At-The-Market(ATM) 수단을 종료했다고 발표했습니다. 이번 결정은 영업활동으로 인한 마이너스 현금흐름의 해소와 최근 현금 잔고 증가 등 회사의 재무 상태 개선을 반영합니다.
CEO 일란 다니엘리는 회사가 이제 더 안정적이며 자본 조달을 위해 더 이상 ATM에 의존할 필요가 없다고 강조하며, 이는 경영진이 주주 가치를 제고하려는 의지를 보여준다고 밝혔습니다.
Precipio (NASDAQ:PRPO), une société spécialisée dans le diagnostic du cancer, a annoncé la résiliation de son dispositif At-The-Market (ATM) avec Alliance Global Partners (AGP). Cette décision reflète l'amélioration de la situation financière de l'entreprise, marquée par l'élimination du flux de trésorerie opérationnel négatif et par les récentes augmentations de la trésorerie disponible.
Le PDG Ilan Danieli a souligné que la société est désormais plus solide et n'a plus besoin de s'appuyer sur l'outil ATM pour lever des capitaux, démontrant l'engagement de la direction à accroître la valeur pour les actionnaires.
Precipio (NASDAQ:PRPO), ein auf Krebsdiagnostik spezialisiertes Unternehmen, hat die Beendigung seines At-The-Market-(ATM)-Instruments mit Alliance Global Partners (AGP) bekanntgegeben. Die Entscheidung spiegelt die verbesserte finanzielle Lage des Unternehmens wider, die sich durch die Beseitigung des negativen operativen Cashflows und die jüngsten Zunahmen der Barbestände zeigt.
CEO Ilan Danieli betonte, dass das Unternehmen nun stärker aufgestellt sei und nicht mehr auf das ATM-Instrument für Kapitalbeschaffungen angewiesen sei, was das Engagement des Managements zur Steigerung des Aktionärswerts unterstreiche.
- Elimination of negative cash flow from operations
- Increased cash balance position
- Reduced reliance on dilutive financing instruments
- None.
Management Decision Further Reinforces Commitment to Responsible Capital Management
NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has terminated its ATM (At-The-Market) instrument with investment bank Alliance Global Partners (AGP).
“Our Company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations, and our recent increases of our cash balance, we now have confidence that we no longer have to rely on a tool like this for capital raises for the Company,” said Ilan Danieli, Precipio’s CEO. “Management is committed to creating shareholder value, and this termination is one more step in that direction.”
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523
FAQ
Why did Precipio (PRPO) terminate its ATM program in September 2025?
What does the ATM termination mean for Precipio (PRPO) shareholders?
What is Precipio's (PRPO) current financial position in 2025?
Who was Precipio's (PRPO) ATM agreement with?
